You reviewed .... for this content
out of 5
5...
4...
3...
2...
1...
Charles University of Prague, Prague (Czechia)
Specialities : Acute Coronary Syndromes , Acute Cardiac Care, Acute Coronary Syndromes
Follow me on:
Case 2 - My P2Y12 inhibitor choice for a patient presenting with STEMI.
Event : ESC Congress 2020
Intense antithrombotic therapy is necessary for long-term treatment in patients with symptomatic peripheral artery disease after acute myocardial infarction and primary PCI
Dual antithrombotic therapy is similarly effective to triple therapy in preventing thrombotic events in patients with atrial fibrillation and acute coronary syndrome
Event : ESC Congress 2019
MiR-126-3P and MiR-223-3p in Prediction of Thrombotic Risk in Patients with Acute Myocardial Infarction and Primary Angioplasty, The Prague-18 Genetic Sub-study
Predictors and case fatality rate of perioperative major cardiovascular events in cardiac patients undergoing non-cardiac surgery.
Event : ESC Congress 2017
Administration of intravenous fentanyl and laboratory efficacy of new p2y12 receptor antagonists in patients with STE myocardial infarction
Event : Acute Cardiovascular Care 2015
Number of severe bleeding complications according to classification used: is unified classification of bleeding complications really necessary?
Event : ESC Congress 2015
The Killip classification in prediction of laboratory efficacy Of P2Y12 receptor inhibitors in patients with STE myocardial infarction
Comparison of laboratory efficacy of P2Y12 receptor antagonists and predictors of high on-treatment platelet reactivity.
Event : ESC Congress 2014
Dose of aspirin does not inluence laboratory antiplatelet efficacy of P2Y12 inhibitors
Event : ESC Congress 2013
Values of osteoprotegerin in aortic valve tissue differ significantly between calcified aortic valve stenosis and normal aortic valve and are influenced by the presence of coronary atherosclerosis
Get your access to resources
Our mission: To reduce the burden of cardiovascular disease
